J&J Sees 250,000 Ebola Vaccine Doses Ready for Trials By May

Johnson & Johnson plans to roll out an Ebola vaccine it is working on developing for clinical trials by May. The vaccine combines a shot from its Janssen unit in the Netherlands with one developed by Danish biotechnology company Bavarian Nordic. J&J is investing $200 million to accelerate and expand production of the vaccine. It's also licensing Bavarian's vaccine and buying new shares in the company in a potential investment reaching over $187 million. J&J's Chief Scientific Officer Paul Stoffels says the treatment will be tested in healthy volunteers in January and the companies' aim is to produce 1 million doses in 2015. That testing will go forward only if the vaccines prove safe and trigger an adequate immune-system response in volunteers during clinical trials that are either underway or planned in Europe, Africa and the United States.